MEDIVATION AND ASTELLAS ANNOUNCE FINAL RESULTS FROM THE PHASE 3 PREVAIL TRIAL OF ENZALUTAMIDE IN MEN WITH METASTATIC PROSTATE CANCER PROGRESSING ON ANDROGEN DEPRIVATION THERAPY

Oprettet 29/01/2014 – 14:59

Study demonstrates statistically significant benefits in overall survival, radiographic progression-free survival, and a delay (17 months) in the time to initiation of chemotherapy.

Skriv et svar

Din e-mailadresse vil ikke blive publiceret. Krævede felter er markeret med *